We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+10.99%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.61B
AUM Growth
+$341M
Cap. Flow
+$76.3M
Cap. Flow %
2.11%
Top 10 Hldgs %
74.41%
Holding
28
New
–
Increased
15
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$28.2M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$26.6M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$24.8M
4
INCY icon
Incyte
INCY
+$19.4M
5
RDUS
Radius Health, Inc.
RDUS
+$18.1M

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$66.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.39M
3
CELG
Celgene Corp
CELG
+$8.85M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$7.18M
5
JUNO
Juno Therapeutics, Inc.
JUNO
+$4.43M

Sector Composition

Rank Sector Weight
1 Healthcare 91.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$464M 12.85%
3,184,298
-65,000
-2% -$8.85M
INCY icon
2
Incyte
INCY
$24.4B
$428M 11.85%
3,668,322
+153,500
+4% +$19.4M
IONS icon
3
Ionis Pharmaceuticals
IONS
$9.4B
$399M 11.03%
7,861,934
+507,839
+7% +$26.6M
GILD icon
4
Gilead Sciences
GILD
$165B
$225M 6.22%
2,774,596
– –
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$126B
$224M 6.21%
1,475,445
– –
NBIX icon
6
Neurocrine Biosciences
NBIX
$16.6B
$212M 5.87%
3,462,753
+16,201
+0.5% +$855K
RDUS
7
DELISTED
Radius Health, Inc.
RDUS
$212M 5.87%
5,498,799
+460,000
+9% +$18.1M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$190M 5.26%
1,354,428
– –
AGIO icon
9
Agios Pharmaceuticals
AGIO
$1.93B
$184M 5.08%
2,749,998
-119,530
-4% -$7.18M
HALO icon
10
Halozyme
HALO
$12.2B
$150M 4.15%
8,626,051
+360,747
+4% +$4.89M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$29.3B
$131M 3.61%
1,111,338
-110,000
-9% -$9.39M
TSRO
12
DELISTED
TESARO, Inc.
TSRO
$129M 3.56%
996,193
+118,203
+13% +$14.7M
ESPR
13
DELISTED
Esperion Therapeutics
ESPR
$105M 2.91%
2,097,964
+584,422
+39% +$28.2M
JUNO
14
DELISTED
Juno Therapeutics, Inc.
JUNO
$92.2M 2.55%
2,055,000
-130,000
-6% -$4.43M
REGN icon
15
Regeneron Pharmaceuticals
REGN
$80.8B
$91.7M 2.54%
205,000
+25,000
+14% +$11.9M
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$68.1M 1.88%
1,092,439
+185,000
+20% +$14.5M
MYOV
17
DELISTED
Myovant Sciences Ltd.
MYOV
$53.8M 1.49%
3,477,882
+160,711
+5% +$1.95M
MGNX icon
18
MacroGenics
MGNX
$257M
$44.4M 1.23%
2,400,412
+50,300
+2% +$871K
AVXS
19
DELISTED
AveXis, Inc. Common Stock
AVXS
$39M 1.08%
402,800
– –
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$34.7M 0.96%
2,200,000
+50,000
+2% +$734K
FPRX
21
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$31.8M 0.88%
777,500
– –
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$28.2M 0.78%
485,719
+230,000
+90% +$24.8M
ALDR
23
DELISTED
Alder Biopharmaceuticals
ALDR
$27.8M 0.77%
2,266,008
+325,000
+17% +$3.39M
PRTA icon
24
Prothena Corp
PRTA
$450M
$22.7M 0.63%
350,000
– –
CDTX
25
DELISTED
Cidara Therapeutics
CDTX
$10.8M 0.3%
66,764
+11,635
+21% +$1.66M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q3 2017 Portfolio in Review

As of Q3 2017, BB Biotech held 28 positions worth $3.61B, up 10% from $3.27B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Trading was light in Q3 2017: portfolio turnover was 3.6%. BB Biotech opened no new positions and exited 1, leaving the 28-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier.

  • BB Biotech added most to Esperion Therapeutics in Q3 2017, an estimated $28.2M increase.
  • BB Biotech's biggest Q3 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $9.39M.
  • BB Biotech fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $66.3M.
  • BB Biotech's ten largest holdings make up 74% of its $3.61B portfolio in Q3 2017.
  • BB Biotech opened 0 new positions and closed 1 in Q3 2017.
  • BB Biotech's portfolio value rose 10% quarter-over-quarter to $3.61B.

Based on BB Biotech's 13F filing for Q3 2017, filed 13 Nov 2017.